<DOC>
	<DOCNO>NCT01478620</DOCNO>
	<brief_summary>The objective study assess safety impact non-antibiotic therapy approach Canephron® N management strategy uncomplicated low urinary tract infection ( UTIs ) .</brief_summary>
	<brief_title>Safety Efficacy Canephron® N Management Uncomplicated Urinary Tract Infections ( uUTI )</brief_title>
	<detailed_description>250 patient total 7-day treatment period Canephron® N ( 2 tablet three time day ) follow-up period Day 37 . A total three visit plan Day 0 ( screening , start study treatment ) , Day 7 ( end study treatment ) Day 37 ( end study visit ) . Additional visit perform anytime Day 1 Day 37 deem necessary investigator . In case patient experience consistent worsen symptom may offer antibiotic therapy discretion investigator time . In case Canephron® N intake stop . At least 50 % patient , i.e . 125 subject , receive 7-day treatment Canephron® N. If less subject available recruitment subject continue required number 125 subject reach . Due withdrawal study Russia total study population reduce 125 patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<criteria>Main Female outpatient age 1865 year ( inclusive ) . Patients suffer symptom uncomplicated low urinary infection screening . Patients must total sum score least six symptom dysuria , frequency urgency . Development symptom within maximum 6 day screen . Willing refrain consuming prohibit concomitant medication product . Nonlactating female patient , surgically sterile ( documented bilateral oophorectomy and/or hysterectomy ) postmenopausal ( cessation menses 1 year ) , patient childbearing potential negative pregnancy test screen willing use effective contraception method ( intrauterine device [ IUD ] , hormonal contraceptive ) study . Main Any sign evoke complicate UTI , pyelonephritis and/or concomitant vulvovaginitis Any condition may lead complicated infection ( , renal disease , urinary tract abnormality past urinary surgery , urine catheterization , etc ) . Chronic infection urinary tract require intravenous pyelogram ( IVP ) , ultrasound cystoscopy . Current sign symptom severe , progressive uncontrolled lifethreatening systemic disease i.e . renal , hepatic , haematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral disease . Other acute infection ( except UTI ) require antibiotic treatment . Patients receive treatment presume proven urinary tract infection within 4 week prior study entry . Antibiotic , immunosuppressive immunostimulant ( incl . vaccine ) therapy within 4 week prior study entry . Patients known history anatomical genitourinary ( GU ) anomalies GU surgery within 6 month prior study entry . Patients know clinically significant abnormality screen physical examination , laboratory test vital sign . Peptic ulcer hypersensitivity and/or idiosyncrasy centaury herb , lovage root , rosemary leave one ingredient investigational medicinal product . Rare hereditary problem fructose intolerance , glucosegalactose malabsorption sucraseisomaltase insufficiency , galactose intolerance lactase deficiency . Patients history severe drug allergy hypersensitivity . Known Human Immunodeficiency Virus ( HIV ) seropositivity .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>